NPR1 Agonists
TL;DR
NPR1 (natriuretic peptide receptor 1) agonists are a drug class designed to mimic the beneficial cardiovascular effects of natriuretic peptides (ANP, BNP) in heart failure — vasodilation, natriuresis, RAAS inhibition. The lead candidate, XXB750 (Novo Nordisk, monoclonal antibody), produced paradoxical functional antagonism in a Phase 2 HFrEF trial: it raised NT-proBNP, lowered cGMP, and caused a 25% death/worsening-HF rate vs 0% on placebo. The trial was terminated early; the program was discontinued. This is a first-in-class failure for antibody-based NPR1 agonism in heart failure. It does not affect downstream cGMP-targeting drugs such as vericiguat.
Why it matters for Vitals
- Safety case study: XXB750 is a landmark example of a rationally designed agonist producing the opposite effect in its intended disease population — relevant for coaching on cardiovascular drug risks and trial literacy
- Biomarker interpretation: NT-proBNP changes during NPR1-targeted therapy can be paradoxical — not a simple biomarker for efficacy
- HRV and wearable monitoring: Patients on related cGMP pathway drugs (vericiguat, riociguat) may show distinct cardiovascular signatures; XXB750 failure illustrates why monitoring is essential during novel mechanism development
- No active patient risk: The XXB750 program was discontinued; no patients are currently on this drug
- Clinical trial context: The DMC-triggered early termination and 0% vs 25% event split is a useful reference for understanding how safety signals emerge in drug development
Key facts
- NPR1 (guanylyl cyclase A): Transmembrane receptor activated by ANP/BNP; converts GTP to cGMP, mediating vasodilation, natriuresis, diuresis, and RAAS/sympathetic inhibition
- XXB750: Human monoclonal antibody designed as NPR1 agonist; first-in-class for antibody-based NPR1 agonism in HFrEF
- Phase 2 RCT (NCT06142383): N=136, HFrEF (LVEF <50%), 16-week primary endpoint; terminated early by Data Monitoring Committee
- Doses studied: 60 mg (n=26), 120 mg (n=55) vs placebo (n=29) vs open-label sacubitril/valsartan (n=25)
- Result — NT-proBNP: Increased ratio 1.34 (95% CI 1.07–1.66) in pooled XXB750 arms — opposite of intended agonist effect
- Result — cGMP: Decreased ratio 0.77 (95% CI 0.65–0.91) — opposite of expected
- Safety outcome: Death or worsening HF — 25% XXB750 vs 8% sacubitril/valsartan vs 0% placebo
- Source: Nature Medicine, PMID 41912806 (March 2026); preclinical in Nature, PMID 39261724
- Program status: Discontinued by Novo Nordisk
Mechanism summary
NPR1 / Natriuretic Peptide Pathway
Natriuretic peptides (ANP, BNP, CNP) are released by cardiac atria and ventricles in response to wall stress. They activate NPR1 (guanylyl cyclase A), which converts GTP to cGMP. cGMP mediates:
- vascular smooth muscle relaxation → vasodilation
- sodium excretion → natriuresis
- water excretion → diuresis
- inhibition of RAAS and sympathetic nervous system
All of these are theoretically beneficial in heart failure with reduced ejection fraction (HFrEF).
Paradoxical Functional Antagonism in HF
XXB750 was designed to directly agonize NPR1, bypassing the need for elevated endogenous natriuretic peptides. In healthy/normochronic states (preclinical models, Nature 2024), it functioned as a genuine NPR1 agonist. In HF patients, it did the opposite:
| Parameter | Expected (NPR1 agonism) | Observed (XXB750 in HFrEF) |
|---|---|---|
| NT-proBNP | Decrease | Increase (ratio 1.34) |
| cGMP | Increase | Decrease (ratio 0.77) |
| HF events | Decrease | 25% vs 0% placebo |
The mechanistic explanation for this disease-state reversal is not yet published. Hypotheses include: receptor density/shedding changes in chronic HF, competition with chronically elevated endogenous natriuretic peptides, or antibody-specific partial agonist dynamics at saturating ligand concentrations. None of these are confirmed.
What the current evidence suggests
- Confirmed (Phase 2 RCT primary data): XXB750 raised NT-proBNP and lowered cGMP in HFrEF patients; the 25% vs 0% adverse event differential is statistically and clinically meaningful
- Confirmed: The drug functioned as a functional antagonist of the natriuretic peptide system in this population
- Supported (mechanistic inference): Antibody-based NPR1 agonism behaves differently from small-molecule downstream sGC stimulation in the high-natriuretic-peptide milieu of HF; this is plausible but not proven
- Unsupported: No mechanistic explanation for the paradoxical reversal has been published; the pre-clinical-to-human disconnect remains unexplained
- No relevance to sGC stimulators: Vericiguat, riociguat work downstream at sGC and are not implicated by the XXB750 failure; they have independent Phase 3 evidence (VICTORIA for vericiguat)
Clinical Trial Results (XXB750 Phase 2 NCT06142383)
| Arm | NT-proBNP change | cGMP change | Death/worsening HF |
|---|---|---|---|
| XXB750 60 mg (n=26) | ↑ (pooled ratio 1.34) | ↓ (pooled ratio 0.77) | 25% (composite) |
| XXB750 120 mg (n=55) | ↑ (pooled ratio 1.34) | ↓ (pooled ratio 0.77) | 25% (composite) |
| Placebo (n=29) | reference | reference | 0% |
| Sacubitril/valsartan (n=25, open-label) | ↓ ratio 0.70 | ↑ ratio 1.38 | 8% |
Primary endpoint: Change in NT-proBNP at 16 weeks — not met; XXB750 worsened NT-proBNP.
Trial termination: DMC stopped the study due to excess adverse events in XXB750 arms. No further dosing occurred.
Source: Borlaug BA et al., Nature Medicine, PMID 41912806 (March 2026).
Safety Signal
The safety signal is the defining feature of this drug class’s current evidence base:
- 25% composite event rate (death or worsening heart failure) in pooled XXB750 arms vs 0% on placebo — the primary safety concern
- NT-proBNP increase (ratio 1.34) indicates the drug worsened cardiac hemodynamic stress, not merely failed to improve it
- cGMP decrease (ratio 0.77) confirms the drug was functionally inhibiting rather than activating the natriuretic peptide pathway
- Dose-independent: Both 60 mg and 120 mg arms showed the same directional effect on NT-proBNP and cGMP; the safety signal was not clearly dose-dependent
No patients should currently be on XXB750 — the program was discontinued.
Comparison to Existing NPR1-Targeting Drugs
| Drug | Mechanism | Target | HF indication | Status | Outcome |
|---|---|---|---|---|---|
| XXB750 | NPR1 agonist antibody | NPR1 (membrane) | HFrEF | Discontinued | Paradoxical antagonism; 25% adverse events |
| Vericiguat (BAY 1021189) | sGC stimulator | Soluble guanylyl cyclase (downstream) | HFrEF | Approved | Modest benefit in VICTORIA trial |
| Nesiritide | Recombinant BNP | NPR1 (natriuretic peptide delivery) | Acute HF | Approved (limited use) | Neutral mortality; renal harm signal |
| Riociguat | sGC stimulator | sGC | PAH/CTEPH | Approved | Not for HF |
| Cinaciguat/praliciguat | sGC activator | sGC | Acute HF | Discontinued | No clear clinical benefit |
Key distinction: Vericiguat and riociguat bypass NPR1 entirely by targeting sGC directly. XXB750 attempted direct receptor agonism. The failure of XXB750 does not indict the cGMP pathway in heart failure — that pathway remains therapeutically valid, as demonstrated by vericiguat.
Vitals Cardiovascular Monitoring Relevance
HRV Implications
- No direct HRV data from the XXB750 trial — the drug was discontinued before wearable substudy analysis could be completed
- Mechanistic inference: cGMP elevation is generally associated with vagal tone enhancement; the observed cGMP decrease in XXB750 patients suggests possible HRV deterioration, but this was not measured as a prespecified endpoint
- For patients on related drugs (vericiguat): cGMP pathway modulation may affect HRV over time; monitor for directional changes in RMSSD and rMSSD during initiation or dose changes
NT-proBNP Interpretation
- Paradoxical elevation during intended NPR1 agonism is the central finding — NT-proBNP cannot be used as a simple efficacy biomarker for NPR1-targeted agents
- Confound for wearable NT-proBNP estimation: Emerging wearable technologies estimate NT-proBNP from peripheral signals; patients on NPR1-targeted agents may show NT-proBNP patterns that are mechanistically non-linear and should not be interpreted as standard HF progression markers
- Clinical practice: NT-proBNP remains the standard biomarker for HF diagnosis and monitoring; interpretation during experimental NPR1-targeted therapy requires specialist oversight
Training Readiness in HF Patients
- XXB750 illustrates that cardiovascular drugs can produce reverse effects — a relevant lesson for interpreting training readiness signals in HF patients
- For HF patients on sacubitril/valsartan or other guideline-directed therapy: These drugs have proven benefit; the XXB750 case does not generalize to them
- For HF patients considering experimental therapies: XXB750 termination underscores the importance of DMC monitoring and early safety signal detection in novel mechanism drug development
Cardiovascular Risk Context
- The 25% vs 0% event differential is a cardiovascular risk case study for monitoring frameworks in drug development
- Drug-induced worsening of NT-proBNP in HF is a known risk pattern; the XXB750 case is extreme but not without precedent in HF drug development
Risks and Uncertainty
Confirmed
- XXB750 raised NT-proBNP and lowered cGMP in HFrEF patients
- 25% composite adverse event rate vs 0% on placebo
- Program discontinued; no patients currently on XXB750
Mechanistic Uncertainty (not proven)
- No published mechanistic explanation for the paradoxical reversal
- Preclinical agonist activity ≠ human efficacy in disease states with chronic receptor saturation
- Whether other NPR1 antibody programs would show the same pattern is unknown
Open Questions
- Why does antibody-based NPR1 agonism reverse in HF but not in healthy/preclinical models?
- Are any other companies or programs pursuing NPR1 antibody agonism for HF?
- Can NT-proBNP be used as a biomarker for any NPR1-targeted drug, or is it inherently unreliable for this class?
- Long-term outcomes in the 25% of XXB750 patients who had events — not publicly disclosed
Drug Class Implications
- NPR1 agonism via monoclonal antibody is not currently a viable HF therapeutic approach
- This does not affect sGC stimulators (vericiguat) or natriuretic peptide infusion approaches
- The case illustrates the risk of assuming receptor pharmacology in disease states mirrors physiology
Related notes
- XXB750 NPR1 Agonist — detailed XXB750 case study (hub note)
- Guanylyl Cyclase — downstream pathway; relevant to vericiguat (no dedicated note yet)
- Cardiovascular signatures — biometric monitoring (aspirational; no dedicated note yet)
- Natriuretic Peptides — ANP/BNP background (aspirational; no dedicated note yet)